Verwandte Artikel zu Medicinal Product Liability and Regulation

Medicinal Product Liability and Regulation - Hardcover

 
9781841132518: Medicinal Product Liability and Regulation

Críticas

...the book can be strongly recommended to everyone interested in this important and rapidly evolving compartment of the law. -- Ken Oliphant * Yearbook of European Tort Law *

Reseña del editor

The piecemeal developments in product liability reform in Europe have their origins in the tragic association of phocomelia in children with thalidomide in 1962. In many ways these events have continued to generate pressure for reform of product liability, especially for the victims of drug-induced injury. This monograph attempts to address the major problems that typify claims for drug-induced injury, as well as highlighting the complex interrelationship between liability exposure and drug regulation. While medicinal products are subject to strict liability under the product liability directive, the claimant may have considerable difficulty in establishing that the relevant product is defective and that it caused the damage. It may also be necessary to overcome the development risk defence where this is pleaded. The monograph addresses these problems on a comparative jurisprudential basis, and seeks to determine whether medicinal products should be treated as a special case in the field of product liability. It examines the role of epidemiological evidence in assessing causation in product liability cases concerning medicinal products in the light of recent developments in the UK Supreme Court, the United States, Canada and France. In particular, it addresses the difficulties in reconciling the standards of proof in law and science, including the theory that causation can be proved on the balance of probabilities by reference to the doubling of risk of injury. An important case study compares and contrasts the approaches of the UK and the US to the measles, mumps, rubella Litigation. The book also examines the question as to whether compliance with regulatory standards should protect pharmaceutical manufacturers from product liability suits. It seeks to support a via media whereby the victims of drug induced injury can receive justice, while at the same time encouraging drug safety and innovation in drug development.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

  • VerlagBloomsbury 3PL
  • Erscheinungsdatum2013
  • ISBN 10 1841132519
  • ISBN 13 9781841132518
  • EinbandTapa dura
  • Anzahl der Seiten244

Gebraucht kaufen

Zustand: Befriedigend
This is an ex-library book and... Mehr zu diesem Angebot erfahren

Versand: EUR 14,27
Von Vereinigtes Königreich nach USA

Versandziele, Kosten & Dauer

In den Warenkorb

Beste Suchergebnisse beim ZVAB

Beispielbild für diese ISBN

Goldberg, R
Verlag: Hart Publishing, 2013
ISBN 10: 1841132519 ISBN 13: 9781841132518
Gebraucht Hardcover

Anbieter: Anybook.com, Lincoln, Vereinigtes Königreich

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings. In good all round condition. Dust jacket in fair condition. Artikel-Nr. 9195898

Verkäufer kontaktieren

Gebraucht kaufen

EUR 75,09
Währung umrechnen
Versand: EUR 14,27
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

Anzahl: 1 verfügbar

In den Warenkorb

Foto des Verkäufers

Goldberg, Richard
Verlag: BLOOMSBURY 3PL, 2013
ISBN 10: 1841132519 ISBN 13: 9781841132518
Neu Hardcover

Anbieter: moluna, Greven, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Gebunden. Zustand: New. This monograph attempts to address the major problems that typify claims for drug-induced injury, as well as highlighting the complex interrelationship between liability exposure and drug regulation.&Uumlber den AutorRichard Goldber. Artikel-Nr. 597052092

Verkäufer kontaktieren

Neu kaufen

EUR 183,13
Währung umrechnen
Versand: EUR 48,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer

Anzahl: Mehr als 20 verfügbar

In den Warenkorb

Foto des Verkäufers

Richard Goldberg
ISBN 10: 1841132519 ISBN 13: 9781841132518
Neu Hardcover

Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Buch. Zustand: Neu. Neuware - The piecemeal developments in product liability reform in Europe have their origins in the tragic association of phocomelia in children with thalidomide in 1962. In many ways these events have continued to generate pressure for reform of product liability, especially for the victims of drug-induced injury. This monograph attempts to address the major problems that typify claims for drug-induced injury, as well as highlighting the complex interrelationship between liability exposure and drug regulation.While medicinal products are subject to strict liability under the product liability directive, the claimant may have considerable difficulty in establishing that the relevant product is defective and that it caused the damage. It may also be necessary to overcome the development risk defence where this is pleaded. The monograph addresses these problems on a comparative jurisprudential basis, and seeks to determine whether medicinal products should be treated as a special case in the field of product liability. It examines the role of epidemiological evidence in assessing causation in product liability cases concerning medicinal products in the light of recent developments in the UK Supreme Court, the United States, Canada and France. In particular, it addresses the difficulties in reconciling the standards of proof in law and science, including the theory that causation can be proved on the balance of probabilities by reference to the doubling of risk of injury. An important case study compares and contrasts the approaches of the UK and the US to the measles, mumps, rubella Litigation.The book also examines the question as to whether compliance with regulatory standards should protect pharmaceutical manufacturers from product liability suits. It seeks to support a via media whereby the victims of drug induced injury can receive justice, while at the same time encouraging drug safety and innovation in drug development. Artikel-Nr. 9781841132518

Verkäufer kontaktieren

Neu kaufen

EUR 249,48
Währung umrechnen
Versand: EUR 32,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer

Anzahl: 2 verfügbar

In den Warenkorb